Thoughts on Autolus Suitors for AUTO3
On Wednesday, January 13, Autolus disclosed at JPM 2021 their intention to develop and commercialize AUTO3 through a partnership with another company (see previous insight). Below, Celltelligence provides thoughts on the likelihood of Autolus partnering with companies such as Merck, AZ, Pfizer, Takeda, Roche, GSK, and JNJ.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.